Highly multiplexed reporter carrier systems

• US 20020106648A1
• Filed: 05/07/2001
• Published: 08/08/2002
• Est. Priority Date: 05/05/2000
• Status: Abandoned Application

• Current Assignee: Agilix Corp. (Revvity, Inc.)
• Original Assignee: Agilix Corp. (Revvity, Inc.)
• Inventors: Chait, Brian T., Lizardi, Paul M., Latimer, Darin R.
• Application Number:
  US09/850,539
• Publication Number:
  US 20020106648A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 1/047 Simultaneous synthesis of different peptide species; Peptide libraries
• CPC Class Codes: C07K 1/13 Labelling of peptides
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: C07K 7/08 having 12 to 20 amino acids gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68
• CPC Class Codes: C12Q 1/6816 characterised by the detection means C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/682 Signal amplification
• CPC Class Codes: C12Q 2563/155 Particles of a defined size, e.g. nanoparticles
• CPC Class Codes: C12Q 2563/167 Mass label
• CPC Class Codes: G01N 33/543 with an insoluble carrier for immobilising immunochemicals
• CPC Class Codes: G01N 33/54346 Nanoparticles
• CPC Class Codes: G01N 33/58 involving labelled substances G01N33/53 takes precedence
• CPC Class Codes: G01N 33/587 Nanoparticles

Abstract

Disclosed are a composition and a method for a multiplexing-optimized reporter system. The system is designed for the simultaneous detection of dozens or even hundreds of analytes. The analytes may be present on the surface of cells in suspension, on the surface of cytology smears, on the surface of histological sections, on the surface of DNA microarrays, on the surface of protein microarrays, on the surface of beads, or any other situation where complex samples need to be studied. The disclosed composition accomplishes this detection by associating specific binding molecules—which interact with desired targets—with numerous tag molecules in a carrier. The numerous tag molecules can be detected and effectively amplify the signal generated from targets.

Claims

1. A method of detecting analytes, the method comprising associating one or more reporter carriers with one or more target samples, wherein the reporter carrier comprises a specific binding molecule, a carrier, and a plurality of decoding tags, and

detecting the decoding tags.

2. The method of claim 1, wherein the carrier is selected from the group consisting of liposomes, microparticles, nanoparticles, virons, phagmids, and branched polymer structures.

3. The method of claim 1, wherein the carrier is a liposome or microbead.

4. The method of claim 3, wherein the liposomes are unilamellar vesicles.

5. The method of claim 4, wherein the vesicles have an average diameter of 150 to 300 nanometers.

6. The method of claim 3, wherein the liposome has an internal diameter of 200 nanometers.

7. The method of claim 1, wherein the carrier is a dendrimer.

8. The method of claim 7, wherein the dendrimer is contacting a macromolecule selected from the group consisting of DNA, RNA, and PNA.

9. The method of claim 8, wherein the macromolecule is an oligonucleotide between 20 and 300 nucleotides in length.

10. The method of claim 1, wherein the specific binding molecule is selected from the group consisting of antibodies, ligands, binding proteins, receptor proteins, haptens, aptamers, carbohydrates, synthetic polyamides, and oligonucleotides.

11. The method of claim 1, wherein the specific binding molecule is a binding protein.

12. The method of claim 11, wherein the binding protein is a DNA binding protein.

13. The method of claim 11, wherein the DNA binding protein contains a motif selected from the group consisting of a zinc finger motif, leucine zipper motif, and helix-turn-helix motif.

14. The method of claim 1, wherein the specific binding molecule is an oligonucleotide.

15. The method of claim 14, wherein the oligonucleotide is between 10 and 40 nucleotides in length.

16. The method of claim 14, wherein the oligonucleotide is between 16 and 25 nucleotides in length.

17. The method of claim 14, wherein the oligonucleotide is a peptide nucleic acid.

18. The method of claim 14, wherein the oligonucleotide forms a triple helix with the target sequence.

19. The method of claim 14, wherein the oligonucleotide comprises a psoralen derivative capable of covalently attaching the oligonucleotide to the target sequence.

20. The method of claim 1, wherein the specific binding molecule is an antibody.

21. The method of claim 20, wherein the antibody binds a protein.

22. The method of claim 1, wherein the decoding tags are selected from the group consisting of oligonucleotides, carbohydrates, synthetic polyamides, peptide nucleic acids, antibodies, ligands, proteins, haptens, zinc fingers, aptamers, mass labels, and any combination of these.

23. The method of claim 1, wherein the decoding tags are peptide nucleic acids.

24. The method of claim 1, wherein the decoding tags are capable of hybridizing specifically to an oligonucleotide reporter tag.

25. The method of claim 24, wherein the length of the oligonucleotide reporter tag is between 10 and 35 nucleotides long.

26. The method of claim 24, wherein the length of the oligonucleotide reporter tag is between 15 and 20 nucleotides long.

27. The method of claim 1, wherein the decoding tags are capable of being detected by a method selected from the group consisting of nuclear magnetic resonance, electron paramagnetic resonance, surface enhanced raman scattering, surface plasmon resonance, fluorescence, phosphorescence, chemiluminescence, resonance raman, microwave, mass spectrometry, mass spectrometry electrophoresis chromatography, and any combination of these.

28. The method of claim 1, wherein the decoding tags are capable of being detected through MALDI-TOF spectroscopy.

29. The method of claim 1, wherein the specific binding molecule and the carrier are covalently linked.

30. The method of claim 1, wherein the carrier and the decoding tags are covalently linked.

31. The method of claim 30, wherein the specific binding molecule and the carrier are covalently linked.

32. The method of claim 1, wherein the specific binding molecule comprises a first oligonucleotide and the carrier comprises a second oligonucleotide which can hybridize to the first oligonucleotide.

33. The method of claim 32, wherein the first oligonucleotide is conjugated to an antibody which binds a protein.

34. The method of claim 1, wherein the decoding tags are isobaric decoding tags.

35. The method of claim 34, wherein a plurality of reporter carriers are associated with one or more target samples, wherein the decoding tags of each reporter carrier are different.

36. The method of claim 35, wherein the all of the decoding tags of all of the reporter carriers have the same mass-to-charge ratio.

37. The method of claim 36, wherein the decoding tags are altered by altering their mass, charge, or both, wherein the altered forms of the decoding tags are distinguished via differences in the mass-to-charge ratio of the altered forms of the decoding tags.

39. The composition of claim 38, wherein the carrier is selected from the group consisting of liposomes, microparticles, nanoparticles, virons, phagmids, and branched polymer structures.

40. The composition of claim 38 wherein the carrier is a liposome.

41. The composition of claim 40, wherein the liposomes are unilamellar vesicles.

42. The composition of claim 41, wherein the vesicles have an average diameter of 150 to 300 nanometers.

43. The composition of claim 40, wherein the liposome has an internal diameter of 200 nanometers.

44. The composition of claim 38, wherein the carrier is a dendrimer.

45. The composition of claim 44, wherein the dendrimer is contacting a macromolecule selected from the group consisting of DNA, RNA, and PNA.

46. The composition of claim 45, wherein the macromolecule is an oligonucleotide between 20 and 300 nucleotides in length.

47. The composition of claim 38, wherein the specific binding molecule is selected from the group consisting of antibodies, ligands, binding proteins, receptor proteins, haptens, aptamers, carbohydrates, synthetic polyamides, and oligonucleotides.

48. The composition of claim 38, wherein the specific binding molecule is a binding protein.

49. The composition of claim 48, wherein the binding protein is a DNA binding protein.

50. The composition of claim 48, wherein the DNA binding protein contains a motif selected from the group consisting of a zinc finger motif, leucine zipper motif, and helix-turn-helix motif.

51. The composition of claim 38, wherein the specific binding molecule is an oligonucleotide.

52. The composition of claim 51, wherein the oligonucleotide is between 10 and 40 nucleotides in length.

53. The composition of claim 51, wherein the oligonucleotide is between 16 and 25 nucleotides in length.

54. The composition of claim 51, wherein the oligonucleotide is a peptide nucleic acid.

55. The composition of claim 51, wherein the oligonucleotide forms a triple helix with the target sequence.

56. The composition of claim 55, wherein the oligonucleotide comprises a psoralen derivative capable of covalently attaching the oligonucleotide to the target sequence.

57. The composition of claim 38, wherein the specific binding molecule is an antibody.

58. The composition of claim 57, wherein the antibody binds a protein.

59. The composition of claim 38, wherein the decoding tags are selected from the group consisting of oligonucleotides, carbohydrates, synthetic polyamides, peptide nucleic acids, antibodies, ligands, proteins, haptens, zinc fingers, aptamers, mass labels, and any combination of these.

60. The composition of claim 38, wherein the decoding tags are peptide nucleic acids.

61. The composition of claim 38, wherein the decoding tags are capable of hybridizing specifically to an oligonucleotide reporter tag.

62. The composition of claim 61, wherein the length of the oligonucleotide reporter tag is between 10 and 35 nucleotides long.

63. The composition of claim 61, wherein the length of the oligonucleotide reporter tag is between 15 and 20 nucleotides long.

64. The composition of claim 38, wherein the decoding tags are capable of being detected by a method selected from the group consisting of nuclear magnetic resonance, electron paramagnetic resonance, surface enhanced raman scattering, surface plasmon resonance, fluorescence, phosphorescence, chemiluminescence, resonance raman, microwave, mass spectrometry, mass spectrometry electrophoresis chromatography, and any combination of these.

65. The composition of claim 38, wherein the decoding tags are capable of being detected through MALDI-TOF spectroscopy.

66. The composition of claim 38, wherein the specific binding molecule and the carrier are covalently linked.

67. The composition of claim 38, wherein the carrier and the decoding tags are covalently linked.

68. The composition of claim 67, wherein the specific binding molecule and the carrier are covalently linked.

69. The composition of claim 38, wherein the specific binding molecule comprises a first oligonucleotide and the carrier comprises a second oligonucleotide which can hybridize to the first oligonucleotide.

70. The composition of claim 69, wherein the first oligonucleotide is conjugated to an antibody which binds a protein.

71. The composition of claim 38, wherein the decoding tags are isobaric decoding tags.

38. A composition for detecting an analyte comprising a specific binding molecule, a carrier, and a plurality of decoding tags.